Pregnancy Is a Cardiovascular Stress Test.

Hypertensive disorders of pregnancy are treated as acute obstetric events. The 20-year cardiovascular evidence is clear. The billing architecture has not caught up.

What the evidence actually says

Preeclampsia is defined obstetrically as pregnancy-induced hypertension with proteinuria or end-organ dysfunction, affecting 5 to 8 percent of all pregnancies. In the current care architecture, the diagnosis is entered into the claim record, managed through delivery, and closed at postpartum discharge. The billing code retires. The patient goes home.

The cardiovascular literature describes a very different event. Pregnancy demands a 30 to 50 percent increase in maternal blood volume, a sustained rise in cardiac output, and a significant shift in insulin sensitivity. When the vascular system fails to adapt smoothly, preeclampsia is the clinical signal that emerges. It is not contained to the pregnancy. It surfaces a latent endothelial and metabolic vulnerability that compounds over the rest of the mother's life.

Adjusted for age, BMI, and diabetes. Each square is the pooled point estimate; the horizontal line is the 95 percent confidence interval. All four intervals exclude RR = 1.0. Source: Wu, Haththotuwa et al., Circulation: Cardiovascular Quality and Outcomes, 2017.

A 2023 update (Countouris et al., Hypertension) confirmed the signal and extended it: women with prior hypertensive disorders of pregnancy (HDP) show the steepest incremental hypertension risk during the five years immediately postpartum, the exact window the current billing architecture has already closed. A separate 2024 Circulation Research review documents peripartum endothelial dysfunction persisting for years, with measurable arterial stiffness and impaired flow-mediated dilation detectable on routine cardiology workup.

Even the epigenetic aging literature now agrees with the cardiology literature. Epigenetic clocks (PhenoAge, GrimAge2) register acceleration in the maternal epigenome during preeclamptic and gestationally-diabetic pregnancies as early as the first trimester. The biological aging signal arrives before the clinical event. The bundled payment architecture discards it anyway.

Why the billing bundle is the architectural failure

Every US-based pregnancy in commercial or Medicaid insurance is reimbursed as a single global obstetric episode. Prenatal care, labor and delivery, and the immediate postpartum visit roll up into one CPT-bundle code. The economic frame makes sense to the payer because it caps utilization. It makes no sense to the patient because it closes her case at the precise moment her cardiovascular risk curve inflects upward.

The sequence above is not speculative. Hauspurg et al. 2019 documented that fewer than 10 percent of women with hypertensive disorders of pregnancy receive any cardiovascular risk assessment within the first year postpartum, and the AHA formally recognised HDP as a major cardiovascular risk factor in its 2021 scientific statement. The clinical guideline exists. The reimbursement architecture does not route patients through it.

Stevens et al. 2017, from a National Inpatient Sample cohort of 955,338 deliveries, priced the immediate cardiovascular consequence of the failed postpartum handoff at approximately $23,000 per maternal CVD episode. That figure sits on the cardiology ledger, not the obstetric ledger. The hospital that delivered the pregnancy does not pay it. Medicare, a decade later, does.

The policy lever is narrow and specific

This is not a call for better awareness. It is a call for one concrete billing change.

• Extend the postpartum bundle to 10 years for HDP pregnancies. Create a CPT code for annual cardiovascular surveillance reimbursable to a care coordinator, triggered automatically when the delivery episode carried a preeclampsia, eclampsia, or gestational-hypertension code (O14 or O13).
• Mandate blood pressure, lipid panel, HbA1c, and symptom-limited follow-up at 6 weeks, 6 months, 1 year, and then annually thereafter. The marginal cost is small. The avoided downstream hospitalisation cost, per Stevens 2017, is $23,000 per prevented episode.
• Make the HDP history visible at the electronic-health-record level for every subsequent primary care and cardiology visit, for the rest of the patient's life. This requires no new technology. It requires a one-line change in EHR default fields.

The intervention converts the preeclampsia diagnosis from an episode-closing obstetric event into the longitudinal cardiovascular biomarker it empirically is. The 4x heart-failure signal that currently generates unpriced cost in Medicare becomes a priced, managed, and surveilled signal in commercial insurance and then in Medicare.

Who this essay is for

This argument is directed at four specific audiences.

• Medicare and CMS bundled-payment designers should extend the obstetric bundle as described, using the existing 2021 AHA scientific statement as clinical justification.
• Commercial payer medical directors have a self-interested reason to move first: the 10-year CVD cost currently transfers to Medicare, but the intermediate 1-5 year hospitalisation costs land in their own books.
• Cardiology and obstetrics professional societies (ACC, AHA, ACOG) should formalise a joint HDP surveillance guideline with reimbursable CPT coding attached.
• Reinsurers underwriting individual life and disability books should treat a documented HDP history as a predictive cardiovascular underwriting variable, not a demographic noise signal. See the reinsurance essay for the treaty-condition mechanics.

The Stevens, Soliman, and Parker cost figures in this essay are drawn from the reproducible cost-reference dataset, the ORI reproducible cost-reference dataset. Every number above has a PMID or DOI attached in the source file.